We recently reiterated our Neutral recommendation on
), which carries a Zacks #3 Rank (short-term Hold rating).
Geron focuses on the development of first-in-class therapeutic
products for the treatment of cancer. The company currently has two
candidates in its pipeline: imetelstat (GRN163L) and GRN1005.
Imetelstat is currently in four phase II studies: non-small cell
lung cancer, essential thrombocythemia, multiple myeloma, and
GRN1005, which became a part of Geron's pipeline following its
agreement with Angiochem, Inc., is currently in two phase II
studies, which are being conducted in patients with brain
metastases arising from non-small cell lung cancer (GRABM-L) and
breast cancer (GRABM-B). Top-line data from these studies should be
out by the end of the second quarter of 2013.
In mid-November 2011, Geron, an erstwhile leader in stem cell
research, announced its intention to exit the stem cell therapy
market. Geron's decision was based on a strategic review. Given the
current economic environment of capital scarcity and uncertainty,
Geron decided to focus on its oncology program which has several
important milestones coming up over the next 20 months.
While the company's decision to focus on oncology should deliver
in the long-term, we expect the stock to remain range-bound in the
near term given the lack of catalysts. Results on the oncology
candidates should start coming out in late 2012 - we prefer to
remain on the sidelines until we see data on these candidates.
GERON CORP (
): Free Stock Analysis Report
To read this article on Zacks.com click here.